Results 101 to 110 of about 6,563 (227)

Comparing the effects of low-level laser therapy and gaseous ozone as a preventive measure on medication-related osteonecrosis of the jaws following tooth extraction: a rat model

European Journal of Medical Research
Objectives Use of numerous medications such as tyrosine kinase inhibitors (sunitinib), monoclonal antibodies (bevacizumab), fusion proteins (aflibercept), mTOR inhibitors (everolimus), radiopharmaceuticals (radium 223), selective estrogen receptor ...
Öznur Özalp, Oğuzcan Göksu, Havva Serap Toru, Mehmet Ali Altay, Alper Sindel   +4 more
doaj   +1 more source

Risk of Osteonecrosis of the Jaw in Patients Treated with Zoledronic or Alendronic Acid: A Systematic Review

Medicina
Background and Objectives: Bisphosphonates (BP) like zoledronic acid (ZA) and alendronic acid (AA) are used for osteoporosis (OP) or other bone-related conditions as well as to prevent the spread of metastases and in rheumatoid arthritis treatment ...
Aine Jakonyte, Egle Gustainyte, Zygimantas Petronis, Aviad Hafizov, Audra Janovskiene, Dainius Razukevicius   +5 more
doaj   +1 more source

Osteonecrose da mandíbula em paciente portador de mieloma múltiplo: patologia secundária ao uso do pamidronato Jaw osteonecrosis in a patient suffering from multiple myeloma: pathology secondary to pamidronate therapy

Revista Brasileira de Hematologia e Hemoterapia, 2005
Descreveremos a ocorrência de osteonecrose da mandíbula associada ao uso de pamidronato (Aredia ) em uma paciente portadora de mieloma múltiplo. Apesar de não ser possível provar definitivamente a associação entre a terapia com bisfosfonatos e a ...
Andréia C. Melo, Marcos Bastos, Maria R. Bastos, Adrieli S. Loureiro, Sérgio S. Araújo   +4 more
doaj   +1 more source

SCD1 Regulates Osteoclast Differentiation by Modulating Arachidonic Acid Metabolism and Mitochondrial Homeostasis

The FASEB Journal, Volume 40, Issue 10, 31 May 2026.
This graphical abstract illustrates that SCD1 inhibition by A939572 or the targeted nanovesicle POCM‐NP@A939572 reprograms arachidonic acid metabolism via the COX1‐HPGDS‐PGD2 axis and impairs mitochondrial homeostasis, thereby suppressing osteoclastogenesis and alleviating bone loss in osteoporosis.
Yihao Zhao, Xiaoan Wei, Haihao Wu, Chengjun Yao, Zeyu Zheng, Weishao Chen, Zhenhua Feng, Bao Huang, Zimin Cai, Qize Xue, Jian Chen, Fengdong Zhao, Junhui Liu   +12 more
wiley   +1 more source

Systemic Ozone Therapy Improves Oral Hard and Soft Tissue Healing in Medication-Related Osteonecrosis of the Jaw (MRONJ): A Study in Senescent Female Rats

Biomedicines
Background/Objectives: Medication-related osteonecrosis of the jaw (MRONJ) is a challenging condition often associated with bisphosphonate use, leading to impaired bone healing and difficult clinical management.
Leonardo Alan Delanora, Tiburtino José de Lima Neto, Tiago Esgalha da Rocha, Glauco Rodrigues Carmo Silveira, Liran Levin, Jamil Awad Shibli, Edilson Ervolino, Carlos Fernando Mourão, Leonardo P. Faverani   +8 more
doaj   +1 more source

The dynamin inhibitor, dynasore, prevents zoledronate-induced viability loss in human gingival fibroblasts by partially blocking zoledronate uptake and inhibiting endosomal acidification [PDF]

Journal of Applied Oral Science
Objective For treatment of medication-related osteonecrosis of the jaw, one proposed approach is the use of a topical agent to block entry of these medications in oral soft tissues.
Jacob KIRBY, Makayla STANDFEST, Jessica BINKLEY, Charles BARNES, Evan BROWN, Tyler CAIRNCROSS, Alex CARTWRIGHT, Danielle DADISMAN, Colten MOWAT, Daniel WILMOT, Theodore HOUSEMAN, Conner MURPHY, Caleb ENGELSMAN, Josh HALLER, Daniel JONES   +14 more
doaj   +1 more source

Osteonecrosis of the jaw in a patient under treatment of osteoporosis with oral bisphosphonate

Autopsy and Case Reports, 2021
Although uncommon in patients under oral therapy, bisphosphonate-related osteonecrosis of the jaw (BRONJ) can be a very severe issue. Early intervention with surgical resection should be the preferable method of treating any stage of the disease ...
Marília A. Figueiredo, Frederico Buhatem Medeiros, Karem López Ortega   +2 more
doaj  

Osteonecrosis of the jaw in association to bisphosphonates [PDF]

, 2008
Thesis (M.A.)--Boston University, 2008.The use of bisphosphonate has become more widespread for the treatment of bone metastasis, multiple myeloma, osteoporosis, Paget's disease and other bone malignancies.
Mattos, Ana Carolina Lopes
core  

Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma

, 2009
Bisphosphonate-associated osteonecrosis of the jaw (BON) is mainly observed in patients with multiple myeloma, and to a lesser extent in breast and prostate cancer patients receiving intravenous treatment with potent bisphosphonates. The incidence of BON
Abildgaard, Niels, Marker, Peter, Vangsted, Annette, Lund, Thomas, Gregersen, Henrik   +4 more
core   +2 more sources

Alendronate-Induced Osteonecrosis of the Jaw in an Elderly Female

International Journal of Gerontology, 2012
Background: In recent years, more and more evidence has demonstrated that a rare symptom, osteonecrosis of the jaw, may be associated with long-term use of bisphosphonates.
Bi-Wei Jan, Hui-Wen Liu, Hung Yu, Shen-Chuan Wang, Chung-Ji Liu   +4 more
doaj   +1 more source